• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕博利珠单抗治疗继发的抗接触蛋白相关蛋白样2抗体自身免疫性边缘叶脑炎

Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.

作者信息

Brown Michael P, Hissaria Pravin, Hsieh Amy Hc, Kneebone Christopher, Vallat Wilson

机构信息

Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia.

出版信息

J Neuroimmunol. 2017 Apr 15;305:16-18. doi: 10.1016/j.jneuroim.2016.12.016. Epub 2017 Jan 18.

DOI:10.1016/j.jneuroim.2016.12.016
PMID:28284337
Abstract

Immune checkpoint inhibitors such as Pembrolizumab are used to restore antitumour immune response. It is important to be vigilant of immune mediated adverse events related to such therapy. We report a case of autoimmune limbic encephalitis with Contactin-Associated Protein-like 2 (CASPR2) antibody secondary to Pembrolizumab therapy for metastatic melanoma.

摘要

帕博利珠单抗等免疫检查点抑制剂用于恢复抗肿瘤免疫反应。警惕与此类治疗相关的免疫介导不良事件非常重要。我们报告了一例继发于帕博利珠单抗治疗转移性黑色素瘤的伴有Contactin相关蛋白样2(CASPR2)抗体的自身免疫性边缘叶脑炎病例。

相似文献

1
Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.帕博利珠单抗治疗继发的抗接触蛋白相关蛋白样2抗体自身免疫性边缘叶脑炎
J Neuroimmunol. 2017 Apr 15;305:16-18. doi: 10.1016/j.jneuroim.2016.12.016. Epub 2017 Jan 18.
2
Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures.脑脊液中抗接触蛋白相关蛋白样 2 抗体阳性的自身免疫性脑炎的特征:以边缘系统症状和癫痫发作为突出表现。
JAMA Neurol. 2016 Sep 1;73(9):1115-24. doi: 10.1001/jamaneurol.2016.1585.
3
Systematic review of the clinical spectrum of CASPR2 antibody syndrome.抗接触蛋白相关蛋白 2 抗体综合征的临床谱系统评价。
J Neurol. 2020 Apr;267(4):1137-1146. doi: 10.1007/s00415-019-09686-2. Epub 2020 Jan 7.
4
Limbic encephalitis in a neuroscientist: CASPR 2 antibody-associated disease after antigen exposure.神经科学家的边缘性脑炎:抗原暴露后 CASPR2 抗体相关疾病。
J Neuroimmunol. 2020 Jun 15;343:577231. doi: 10.1016/j.jneuroim.2020.577231. Epub 2020 Apr 1.
5
Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome.抗接触蛋白相关蛋白2脑炎:抗体滴度、临床表现及预后的相关性
Eur J Neurol. 2017 Jan;24(1):175-186. doi: 10.1111/ene.13180. Epub 2016 Oct 27.
6
Caspr2 antibody limbic encephalitis is associated with Hashimoto thyroiditis and thymoma.接触蛋白相关蛋白2抗体边缘叶性脑炎与桥本甲状腺炎及胸腺瘤有关。
J Neurol Sci. 2014 Jun 15;341(1-2):36-40. doi: 10.1016/j.jns.2014.03.043. Epub 2014 Mar 29.
7
A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report.一名患有LGI1和CASPR2抗体的中国女性莫旺氏综合征患者:病例报告。
BMC Neurol. 2016 Mar 16;16:37. doi: 10.1186/s12883-016-0555-x.
8
Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.抗接触蛋白相关蛋白样 2 抗体相关小脑性共济失调:病例报告及文献复习。
J Neuroimmunol. 2021 Apr 15;353:577515. doi: 10.1016/j.jneuroim.2021.577515. Epub 2021 Feb 3.
9
[F]DPA-714-PET-MRI reveals pronounced innate immunity in human anti-LGI1 and anti-CASPR2 limbic encephalitis.[F]DPA - 714 - PET - MRI显示人类抗LGI1和抗CASPR2边缘性脑炎中存在明显的固有免疫。
J Neurol. 2024 Jun;271(6):3653-3659. doi: 10.1007/s00415-024-12302-7. Epub 2024 Mar 12.
10
[Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications].[边缘叶脑炎:新的细胞膜抗原及具有治疗意义的临床-免疫学分类建议]
Neurologia. 2007 Oct;22(8):526-37.

引用本文的文献

1
Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.与免疫检查点抑制剂相关的抗体阳性副肿瘤性神经系统综合征:一项系统综述
J Neurol. 2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7.
2
The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.治疗药物穿越血脑屏障的渗透:经典案例研究及其临床意义。
Cell Rep Med. 2024 Nov 19;5(11):101760. doi: 10.1016/j.xcrm.2024.101760. Epub 2024 Oct 8.
3
Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.
免疫检查点抑制剂时代的副肿瘤综合征的管理。
Curr Treat Options Oncol. 2024 Jan;25(1):42-65. doi: 10.1007/s11864-023-01157-1. Epub 2024 Jan 10.
4
Epidemic Japanese B encephalitis combined with contactin-associated protein-like 2 antibody-positive autoimmune encephalitis: A case report.流行性乙型脑炎合并接触蛋白相关蛋白样2抗体阳性自身免疫性脑炎:一例报告
World J Clin Cases. 2023 Feb 26;11(6):1379-1384. doi: 10.12998/wjcc.v11.i6.1379.
5
Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature.免疫检查点抑制剂相关自身免疫性脑炎:神经免疫学的罕见新课题——病例报告及文献综述
Brain Sci. 2022 Jun 13;12(6):773. doi: 10.3390/brainsci12060773.
6
Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.免疫相关性无菌性脑膜炎与免疫检查点抑制剂治疗管理策略:系统评价。
J Neurooncol. 2022 May;157(3):533-550. doi: 10.1007/s11060-022-03997-7. Epub 2022 Apr 13.
7
Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.托泊替康治疗后以小脑受累为主的抗 GAD65 抗体相关自身免疫性脑炎:托泊替康一种新型 irAE 的病例报告。
Front Immunol. 2022 Mar 25;13:850540. doi: 10.3389/fimmu.2022.850540. eCollection 2022.
8
Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies.癫痫发生的免疫机制及相关治疗策略
Biomedicines. 2022 Mar 19;10(3):716. doi: 10.3390/biomedicines10030716.
9
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.副肿瘤性自身免疫性神经综合征及免疫检查点抑制剂的作用
Neurotherapeutics. 2022 Apr;19(3):848-863. doi: 10.1007/s13311-022-01184-0. Epub 2022 Jan 18.
10
[Pembrolizumab-associated autoimmune encephalitis in an elderly patient with advanced non-small cell lung cancer. A clinical case].[一名晚期非小细胞肺癌老年患者的帕博利珠单抗相关自身免疫性脑炎。临床病例]
An Sist Sanit Navar. 2021 Aug 20;44(2):291-297. doi: 10.23938/ASSN.0948.